{"id":"NCT01662648","sponsor":"Janssen Pharmaceutica","briefTitle":"Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia","officialTitle":"An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2008-04","completion":"2009-04","firstPosted":"2012-08-10","resultsPosted":"2014-03-26","lastUpdate":"2014-05-05"},"enrollment":1117,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Paliperidone ER","otherNames":[]}],"arms":[{"label":"Paliperidone ER: Lack of efficacy","type":"EXPERIMENTAL"},{"label":"Paliperidone ER: Lack of tolerability, compliance or other","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to explore the efficacy of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who were previously unsuccessfully treated with other oral antipsychotics.","primaryOutcome":{"measure":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Paliperidone ER: Lack of Efficacy","deltaMin":85.19,"sd":24.97},{"arm":"Paliperidone ER: Lack of Tolerability, Compliance or Other","deltaMin":65.45,"sd":28.48}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":512},"commonTop":["Insomnia","Extrapyramidal disorder","Headache","Nausea","Dizziness"]}}